Jeffrey T. L. Smith
CIK: 0001604800
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Zymeworks Inc.
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Jan 12, 2026ZYME
Zymeworks Inc.
Exercise(M)Direct17.7K shares- - Jan 12, 2026ZYME
Zymeworks Inc.
Sale(S)Direct9.3K shares at avg. $22.67$211K - Jan 5, 2026ZYME
Zymeworks Inc.
Exercise(M)Direct20K shares- - Jan 5, 2026ZYME
Zymeworks Inc.
Sale(S)Direct10.5K shares at avg. $25.10$264K - Jan 10, 2025ZYME
Zymeworks Inc.
Award(A)DirectRestricted Stock Unit
53K shares- - Jan 10, 2025ZYME
Zymeworks Inc.
Award(A)DirectStock Option (Right to Buy)
79K shares- - Jan 6, 2025ZYME
Zymeworks Inc.
Exercise(M)Direct20K shares- - Jan 6, 2025ZYME
Zymeworks Inc.
Sale(S)Direct11.1K shares at avg. $14.92$166K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 12, 2026 | ZYME Zymeworks Inc. | Exercise(M) | 17,666 | - | $0 | Direct |
| Jan 12, 2026 | ZYME Zymeworks Inc. | Sale(S) | 9,310 | $22.67 | $211,090 | Direct |
| Jan 5, 2026 | ZYME Zymeworks Inc. | Exercise(M) | 20,000 | - | $0 | Direct |
| Jan 5, 2026 | ZYME Zymeworks Inc. | Sale(S) | 10,538 | $25.10 | $264,471 | Direct |
| Jan 10, 2025 | ZYME Zymeworks Inc. | Award(A) Restricted Stock Unit | 53,000 | - | - | Direct |
| Jan 10, 2025 | ZYME Zymeworks Inc. | Award(A) Stock Option (Right to Buy) | 79,000 | - | - | Direct |
| Jan 6, 2025 | ZYME Zymeworks Inc. | Exercise(M) | 20,000 | - | $0 | Direct |
| Jan 6, 2025 | ZYME Zymeworks Inc. | Sale(S) | 11,110 | $14.92 | $165,807 | Direct |
1-8 of 8 transactions
About Smith Jeffrey T L
Smith Jeffrey T L (SEC CIK 0001604800) files insider reports with the SEC as EVP & Chief Medical Officer of Zymeworks Inc. (ZYME).
Signal8 holds 4 ownership filings by Smith Jeffrey T L, all Form 4s, filed between Jan 6, 2025 and Jan 12, 2026. Those filings report 8 transactions, from Jan 6, 2025 to Jan 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Smith Jeffrey T L's filings is in MIDDLETOWN, DE.
Recent filings by Smith Jeffrey T L
- Jan 12, 2026: Option exercise of ZYME shares (Form 4, code M).
- Jan 12, 2026: Open-market sale of ZYME shares (Form 4, code S).
- Jan 5, 2026: Option exercise of ZYME shares (Form 4, code M).
- Jan 5, 2026: Open-market sale of ZYME shares (Form 4, code S).
- Jan 10, 2025: Grants or awards of ZYME derivative securities (2 lines, Form 4, code A).
Other insiders filing for Zymeworks Inc. (ZYME)
- Schayowitz Adam, EVP, Head of R&D
- Hollywood Mark, EVP & Chief Operating Officer
- Schneider Paul R, EVP, General Counsel
- Platshon Scott, EVP, Chief Business Officer
- Stafford Kristin, EVP, Chief Financial Officer
- Mekan Sabeen, SVP & Chief Medical Officer